Nabsys

The Brown University spinout plans to market its instrument, Nabsys HD-Mapping, for genome mapping, de novo assembly, and structural variant detection. 

At a workshop organized by the Genome in a Bottle consortium last month, Nabsys presented its human genome maps for the first time.

After closing its doors last September, Nabsys has resumed operations, refocusing on its core technology.

2.0 Time

Former CEO Barrett Bready has purchased the recently shuttered Nabsys for $500,000 and the assumption of $100,000 in debt, according to GoLocalProv.

According to local news reports, the company recently closed its facility in Providence, Rhode Island.

Nabsys CEO Steve Lombardi and CSO Tony Shuber spoke with GenomeWeb at last week's JP Morgan conference in San Francisco. 

The companies will combine Nabsys' technology to identify the structural variants with Ariana's clinical data analysis tools.

NabSys has been awarded

This article was originally published Nov. 3.
NEW YORK (GenomeWeb) – Following the recent appointments of a new CEO and CSO, Nabsys is shifting its strategy toward developing a platform for clinical applications, in particular structural variation analysis of cancer genomes.

Quest Diagnostics has elected Jeffrey Leiden to its Board of Directors. Leiden is the chairman, president, and CEO of Vertex Pharmaceuticals.

Pages

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.